Status: Not yet recruiting
A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)
For Phase 1, researchers will explore the safety, and tolerability of PMS-101 and determine the recommended Phase 2 dose (RP2D) using the donor site. For Phase 2a, researchers will compare PMS-101 to a standard-of-care to see if PMS-101 works to treat mid-dermal burns.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Primoris TherapeuticsUpdated: Jul 5, 2024Locations: 1
Eligibility criteria
The combined TBSA of all burns is 10% or less. [+5]
Those who are allergic to or have experienced hypersensitivity to any components... [+25]